Urothelial carcinoma

Summary

Urothelial carcinoma (MONDO:0040679) is a cancer (an umbrella term covering 5 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver) and 456 clinical trials. Molecularly, FGFR3 S249C confers sensitivity to Erdafitinib in Urothelial Carcinoma (CIViC Level B); 5 further subtype–drug associations are mapped below. Top therapeutic interventions include enfortumab vedotin, ipilimumab, and sacituzumab govitecan.

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Cohort genes: 1
• Clinical trials: 456
• Precision-medicine evidence (CIViC): 6 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urothelial carcinoma
Mondo ID	MONDO:0040679
EFO	EFO:0008528
NCIT	C4030
UMLS	C2145472
MedGen	760495
GARD	0025829
Anatomy (UBERON)	UBERON:0001008
Is cancer (heuristic)	yes

Also known as: transitional cell car. -uroth. · transitional cell carcinoma of the urinary tract · transitional cell carcinoma of the urothelial tract · Uroepithelial carcinoma · urothelial carcinoma

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › urothelial carcinoma

Related subtypes (9): malignant prostate phyllodes tumor, urinary bladder cancer, kidney cancer, urethra cancer, multiple endocrine neoplasia type 2B, ureter cancer, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, infiltrating urothelial carcinoma

Subtypes (5): urethra transitional cell carcinoma, bladder transitional cell carcinoma, non-papillary transitional cell carcinoma of the bladder, renal pelvis/ureter urothelial carcinoma, pure squamous carcinoma of the urothelial tract

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
FGFR3	Act	BLADDER,BLCA,HNSC,LUSC,PCM,PLMESO,UTUC	CIViC #23

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FGFR3	Orphanet:15	Achondroplasia
FGFR3	Orphanet:1860	Thanatophoric dysplasia type 1
FGFR3	Orphanet:2363	Lacrimoauriculodentodigital syndrome
FGFR3	Orphanet:251576	Gliosarcoma
FGFR3	Orphanet:251579	Giant cell glioblastoma
FGFR3	Orphanet:35099	Non-syndromic bicoronal craniosynostosis
FGFR3	Orphanet:429	Hypochondroplasia
FGFR3	Orphanet:53271	Muenke syndrome
FGFR3	Orphanet:794	Saethre-Chotzen syndrome
FGFR3	Orphanet:85164	Camptodactyly-tall stature-scoliosis-hearing loss syndrome
FGFR3	Orphanet:85165	Severe achondroplasia-developmental delay-acanthosis nigricans syndrome
FGFR3	Orphanet:93262	Crouzon syndrome-acanthosis nigricans syndrome
FGFR3	Orphanet:93274	Thanatophoric dysplasia type 2

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FGFR3	HGNC:3690	ENSG00000068078	P22607	Fibroblast growth factor receptor 3	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FGFR3	Fibroblast growth factor receptor 3	Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FGFR3	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
skin of hip	1
upper arm skin	1
upper leg skin	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FGFR3	262	broad	marker	upper leg skin, skin of hip, upper arm skin

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FGFR3	4,510

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FGFR3	P22607	15

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
t(4;14) translocations of FGFR3	1	11420.0×	7e-04	FGFR3
Signaling by FGFR3 fusions in cancer	1	11420.0×	7e-04	FGFR3
FGFR3b ligand binding and activation	1	1631.4×	0.003	FGFR3
Signaling by activated point mutants of FGFR3	1	951.7×	0.003	FGFR3
FGFR3c ligand binding and activation	1	878.5×	0.003	FGFR3
Phospholipase C-mediated cascade; FGFR3	1	878.5×	0.003	FGFR3
PI-3K cascade:FGFR3	1	634.4×	0.003	FGFR3
SHC-mediated cascade:FGFR3	1	601.0×	0.003	FGFR3
FRS-mediated FGFR3 signaling	1	543.8×	0.003	FGFR3
Signaling by FGFR3 in disease	1	496.5×	0.003	FGFR3
Negative regulation of FGFR3 signaling	1	439.2×	0.003	FGFR3
PI3K Cascade	1	271.9×	0.005	FGFR3
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.010	FGFR3
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	96.8×	0.012	FGFR3
PIP3 activates AKT signaling	1	66.8×	0.016	FGFR3
RAF/MAP kinase cascade	1	61.1×	0.016	FGFR3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of developmental growth	1	16852.0×	0.001	FGFR3
fibroblast growth factor receptor apoptotic signaling pathway	1	8426.0×	0.001	FGFR3
bone maturation	1	5617.3×	0.001	FGFR3
positive regulation of phospholipase activity	1	3370.4×	0.001	FGFR3
endochondral bone growth	1	1685.2×	0.002	FGFR3
chondrocyte proliferation	1	1053.2×	0.003	FGFR3
positive regulation of tyrosine phosphorylation of STAT protein	1	732.7×	0.004	FGFR3
bone morphogenesis	1	601.9×	0.004	FGFR3
endochondral ossification	1	543.6×	0.004	FGFR3
chondrocyte differentiation	1	300.9×	0.006	FGFR3
cell surface receptor signaling pathway via JAK-STAT	1	290.6×	0.006	FGFR3
fibroblast growth factor receptor signaling pathway	1	285.6×	0.006	FGFR3
bone mineralization	1	271.8×	0.006	FGFR3
MAPK cascade	1	153.2×	0.009	FGFR3
skeletal system development	1	125.8×	0.011	FGFR3
positive regulation of ERK1 and ERK2 cascade	1	85.1×	0.014	FGFR3
positive regulation of MAPK cascade	1	80.6×	0.014	FGFR3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	78.4×	0.014	FGFR3
cell-cell signaling	1	69.6×	0.015	FGFR3
positive regulation of cell population proliferation	1	33.6×	0.030	FGFR3

Therapeutics

Drugs indicated for this disease

3 approved, 24 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Atezolizumab	Approved (phase 4)
Avelumab	Approved (phase 4)
Erdafitinib	Approved (phase 4)
Carboplatin	Phase 3 (in late-stage trials)
Cetrelimab	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Disitamab Vedotin	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Durvalumab	Phase 3 (in late-stage trials)
Enfortumab Vedotin	Phase 3 (in late-stage trials)
Fluorouracil	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Lenvatinib	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Mitomycin	Phase 3 (in late-stage trials)
Nivolumab	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pembrolizumab	Phase 3 (in late-stage trials)
Ramucirumab	Phase 3 (in late-stage trials)
Sasanlimab	Phase 3 (in late-stage trials)
Tislelizumab	Phase 3 (in late-stage trials)
Toripalimab	Phase 3 (in late-stage trials)
Trastuzumab Vedotin	Phase 3 (in late-stage trials)
Tremelimumab	Phase 3 (in late-stage trials)
Valrubicin	Phase 3 (in late-stage trials)
Vinblastine	Phase 3 (in late-stage trials)
Vinflunine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aldesleukin, Bevacizumab, Bicalutamide, Cabazitaxel, Cabozantinib, Cadonilimab, Dexamethasone, Epacadostat, Favezelimab, Guadecitabine, Ipilimumab, Nintedanib, Niraparib, Nogapendekin Alfa, Oxaliplatin, Palbociclib, Pegfilgrastim, Pemetrexed, Pemigatinib, Retifanlimab, Sacituzumab Govitecan, Sodium Chloride, Sulforaphane, Sunitinib, Talazoparib, Tipifarnib, Trebananib, Vadimezan, Vibostolimab.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
FGFR3	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FGFR3	64	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PONATINIB	4	FGFR3
PEMIGATINIB	4	FGFR3
NINTEDANIB	4	FGFR3
FEDRATINIB	4	FGFR3
LENVATINIB	4	FGFR3
AXITINIB	4	FGFR3
SORAFENIB	4	FGFR3
INFIGRATINIB PHOSPHATE	4	FGFR3
INFIGRATINIB	4	FGFR3
ENTRECTINIB	4	FGFR3
CERITINIB	4	FGFR3
VANDETANIB	4	FGFR3
NINTEDANIB ESYLATE	4	FGFR3
BRIGATINIB	4	FGFR3
ERDAFITINIB	4	FGFR3
FUTIBATINIB	4	FGFR3
PAZOPANIB	4	FGFR3
SUNITINIB	4	FGFR3
DASATINIB	4	FGFR3
CRIZOTINIB	4	FGFR3
MIDOSTAURIN	4	FGFR3
LINIFANIB	3	FGFR3
SEMAXANIB	3	FGFR3
BRIVANIB	3	FGFR3
ALISERTIB	3	FGFR3
CEDIRANIB	3	FGFR3
DOVITINIB	3	FGFR3
LESTAURTINIB	3	FGFR3
TANDUTINIB	2	FGFR3
FORETINIB	2	FGFR3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FGFR3	975	Binding:948, Functional:18, ADMET:9

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
FGFR3	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
FGFR3	975

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	FGFR3
NINTEDANIB	4	FGFR3
FEDRATINIB	4	FGFR3
LENVATINIB	4	FGFR3
AXITINIB	4	FGFR3
SORAFENIB	4	FGFR3
INFIGRATINIB PHOSPHATE	4	FGFR3
INFIGRATINIB	4	FGFR3
ENTRECTINIB	4	FGFR3
CERITINIB	4	FGFR3
VANDETANIB	4	FGFR3
NINTEDANIB ESYLATE	4	FGFR3
BRIGATINIB	4	FGFR3
FUTIBATINIB	4	FGFR3
PAZOPANIB	4	FGFR3
SUNITINIB	4	FGFR3
DASATINIB	4	FGFR3
CRIZOTINIB	4	FGFR3
MIDOSTAURIN	4	FGFR3
LINIFANIB	3	FGFR3
SEMAXANIB	3	FGFR3
BRIVANIB	3	FGFR3
ALISERTIB	3	FGFR3
CEDIRANIB	3	FGFR3
DOVITINIB	3	FGFR3
LESTAURTINIB	3	FGFR3
TANDUTINIB	2	FGFR3
FORETINIB	2	FGFR3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	FGFR3
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 456.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	138
Not specified	119
PHASE1	96
PHASE1/PHASE2	63
PHASE3	27
EARLY_PHASE1	8
PHASE4	3
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06862219	PHASE4	RECRUITING	A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT04197089	PHASE4	COMPLETED	Biological Effect of Vitamin D in Patients With Urothelial Carcinoma
NCT05723991	PHASE4	UNKNOWN	Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
NCT03244384	PHASE3	ACTIVE_NOT_RECRUITING	Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03967977	PHASE3	ACTIVE_NOT_RECRUITING	Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT04579224	PHASE3	ACTIVE_NOT_RECRUITING	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04637594	PHASE3	ACTIVE_NOT_RECRUITING	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT05037279	PHASE3	RECRUITING	Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
NCT05078047	PHASE3	RECRUITING	Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT05243550	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05302284	PHASE3	RECRUITING	A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
NCT05911295	PHASE3	ACTIVE_NOT_RECRUITING	Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT06111235	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06196736	PHASE3	RECRUITING	A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
NCT06331299	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06493552	PHASE2/PHASE3	RECRUITING	Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
NCT06524544	PHASE3	RECRUITING	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06592326	PHASE3	RECRUITING	9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
NCT06738251	PHASE3	RECRUITING	A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
NCT06774131	PHASE3	RECRUITING	A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06851663	PHASE2/PHASE3	RECRUITING	Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06857175	PHASE3	RECRUITING	A Study Comparing BL-B01D1 With Chemotherapy of Physician’s Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
NCT07464145	PHASE3	NOT_YET_RECRUITING	A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
NCT07526792	PHASE3	NOT_YET_RECRUITING	SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT00315237	PHASE3	COMPLETED	Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
NCT00942331	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT02426125	PHASE3	COMPLETED	A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
NCT02807636	PHASE3	COMPLETED	Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT03898180	PHASE3	COMPLETED	Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT04688931	PHASE3	TERMINATED	A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05136898	PHASE3	COMPLETED	Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT07342517	PHASE3	WITHDRAWN	A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
NCT00365157	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
NCT02420847	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02717156	PHASE2	ACTIVE_NOT_RECRUITING	Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
NCT02845323	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02989584	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
NCT03047213	PHASE2	ACTIVE_NOT_RECRUITING	Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
NCT03093922	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
NCT03179943	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENFORTUMAB VEDOTIN	4	16
IPILIMUMAB	4	11
SACITUZUMAB GOVITECAN	4	6
CABOZANTINIB	4	5
GEMCITABINE	4	5
ERDAFITINIB	4	4
AVELUMAB	4	3
MITOMYCIN	4	3
PEMIGATINIB	4	3
TORIPALIMAB	4	3
VINFLUNINE	4	3
ATEZOLIZUMAB	4	2
CABAZITAXEL	4	2
CHOLECALCIFEROL	4	2
ERIBULIN MESYLATE	4	2
NIRAPARIB	4	2
PEMBROLIZUMAB	4	2
RELATLIMAB	4	2
RETIFANLIMAB	4	2
RUCAPARIB	4	2
TREMELIMUMAB	4	2
AFATINIB	4	1
BELINOSTAT	4	1
COPANLISIB	4	1
COSIBELIMAB	4	1
DURVALUMAB	4	1
ERGOCALCIFEROL	4	1
HYALURONIDASE (HUMAN RECOMBINANT)	4	1
HYDROXYCHLOROQUINE	4	1
IOPAMIDOL	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 6 predictive associations from 7 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
FGFR3 S249C	Erdafitinib	Sensitivity/Response	CIViC B	EID12953 +1
FGFR1 M563T	Futibatinib	Sensitivity/Response	CIViC C	EID11636
FGFR3 S249C	Futibatinib	Sensitivity/Response	CIViC C	EID11635
FGFR3 Y373C AND FGFR3 N540K	Erdafitinib + Futibatinib	Resistance	CIViC C	EID12704
PIK3CA E545K AND FGFR3 S249C AND FGFR3 N540K	Erdafitinib	Resistance	CIViC C	EID12703
KMT2D Loss-of-function OR KMT2C Loss-of-function	Afatinib + Gefitinib	Sensitivity/Response	CIViC D	EID12775